Page last updated: 2024-12-07
sk&f 85174
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
SK&F 85174: dopamine receptor agonist; RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 132435 |
| CHEMBL ID | 130795 |
| CHEMBL ID | 368456 |
| SCHEMBL ID | 11273914 |
| MeSH ID | M0133426 |
Synonyms (14)
| Synonym |
|---|
| 77386-12-0 |
| 3-allyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1h-3-benzazepine-7,8-diol methanesulfonate |
| sk&f 85174-j |
| skf 85174 |
| sk&f 85174 |
| CHEMBL130795 , |
| 1h-3-benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-3-(2-propenyl)- |
| CHEMBL368456 |
| 3-allyl-6-chloro-1-(4-hydroxy-phenyl)-2,3,4,5-tetrahydro-1h-benzo[d]azepine-7,8-diol |
| bdbm50019389 |
| SCHEMBL11273914 |
| 3-allyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1h-3-benzazepine-7,8-diol |
| DTXSID50998600 |
| 6-chloro-1-(4-hydroxyphenyl)-3-(prop-2-en-1-yl)-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (7)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID59807 | Tested in vivo for change in maximal arterial pressure (MAP)in dog after intravenous dose of 30 mg/kg | 1983 | Journal of medicinal chemistry, Jul, Volume: 26, Issue:7 | 4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists. |
| AID59801 | Tested in vivo for change in maximal arterial pressure (MAP) in dog after intravenous dose of 3 mg/kg | 1983 | Journal of medicinal chemistry, Jul, Volume: 26, Issue:7 | 4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists. |
| AID59792 | Tested in vivo for change in heart rate (HR) in dog after intravenous dose of 3 mg/kg | 1983 | Journal of medicinal chemistry, Jul, Volume: 26, Issue:7 | 4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists. |
| AID59800 | Tested in vivo for change in maximal arterial pressure (MAP) in dog after intravenous dose of 0.3 mg/kg | 1983 | Journal of medicinal chemistry, Jul, Volume: 26, Issue:7 | 4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists. |
| AID59794 | Tested in vivo for change in heart rate (HR) in dog after intravenous dose of 30 mg/kg | 1983 | Journal of medicinal chemistry, Jul, Volume: 26, Issue:7 | 4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists. |
| AID59798 | Tested in vivo for change in heart rate in dog after intravenous dose of 0.3 mg/kg | 1983 | Journal of medicinal chemistry, Jul, Volume: 26, Issue:7 | 4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists. |
| AID62578 | Tested in vitro for dopamine agonist activity in rabbit ear artery after at a dose of 0.3 mg/kg | 1983 | Journal of medicinal chemistry, Jul, Volume: 26, Issue:7 | 4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (85.71) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.99
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.99) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||